Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early boost for Life Medical's anti-adhesion product:

This article was originally published in Clinica

Executive Summary

Life Medical Sciences has taken an early, but important, step closer to becoming the first to gain US approval to market an anti-adhesion product for use in cardiac surgery. A US feasibility trial of the company's REPEL-CV bioresorbable adhesion barrier for reducing post-operative adhesion formation in cardiac surgical procedures has provided preliminary data to support the product's safety and effectiveness, says the Ocean Port, New Jersey firm. Life Medical has submitted the results and a proposed multicentre, pivotal clinical trial protocol to the FDA. The proposed trial is expected to form the basis for obtaining FDA approval to market the product.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel